Latest news and press releases about Lexaria Bioscience Corp. (LEXX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream.
Price
| Price | $3.10 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 1.08 |
| EV / EBITDA | -0.43 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -160.72% |
| Return on Invested Capital | -173.96% |
| Return on Assets | -161.71% |
| Gross Margin | 100.00% |
| Operating Margin | -3973.16% |
| Net Margin | -3985.58% |
Related companies: ALLR · BCTX · CASI · CING · CLSD · CRIS · ENTO
Explore sector: Healthcare · Biotechnology
More sections of LEXX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks